SM

Shabir Madhi

University of the Witwatersrand Johannesburg Faculty of Science, University of Witwatersrand / South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit

Research areas: Medicine · Epidemiology · Pneumonia and Respiratory Infections · Bacterial Infections and Vaccines · Respiratory viral infections research

ORCID iD 0000-0002-7629-0636
Follow

About

Shabir Madhi is Dean of the Faculty of Health Sciences and Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa; and co-founder and co-Director of the African Leadership Initiative for Vaccinology Expertise (ALIVE). Professor Madhi completed his undergraduate and postgraduate training at the University of the Witwatersrand, qualifying as paediatrician in 1996 and obtaining his PhD in 2003.

He currently also holds the positions of Director of the South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit (VIDA), and a member of the National Advisory Group on Immunization in South Africa. His past appointments include being the Director of the National Institute for Communicable Diseases in South Africa (2011-2017) and being South African Research Chair Department of Science and Technology, National Research Foundation, Vaccine Preventable Diseases (2008-2020).

Shabir has co-authored over 750 scientific publications since 1997, and has an H-index of 103. His research has focused on the epidemiology, and clinical development of lifesaving vaccines against pneumonia and diarrheal disease. Over the past decade, he has focussed on vaccines being developed for immunization of pregnant women for the benefit of the women and their young infants. He led the first two COVID-19 vaccine studies undertaken in Africa, and was also involved in multiple clinical and serology epidemiology studies on COVID-19.

Employment

  • University of the Witwatersrand Johannesburg Faculty of Science Dean and Professor of Vaccinology
    2021 - Present
  • University of Witwatersrand / South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit Director
    2013 - Present
  • National Institute for Communicable Diseases Executive Director
    2011 - 2017
  • University of the Witwatersrand Professor of Vaccinology
    2008 - Present
  • Department of Science and Technology, National Research Foundation, Vaccine Preventable Diseases Chairman
    2008 - 2020
  • University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit Co-Director
    2007 - 2013
  • Chris Hani Baragwanath Hospital Honorary Consultant
    1997 - 2007

Education

Projects & Funding

  • Long term follow up of children participating in 1+1 PCV dosing study Bill & Melinda Gates Foundation
    2022 - 2023
  • Correlates of protection against invasive GBS disease MinervaX
    2022 - 2023
  • COVID-19: Vaccine Information Network Bill & Melinda Gates Foundation
    2021 - 2022
  • Assessing the safety of COVID-19 vaccines across large and diverse populations using the 17-country Global Vaccine Data Network Consortium Centers for Disease Control and Prevention
    2021 - 2024
  • MTBVAC in Newborns: Randomised, Double-blind Controlled Phase 3 Trial to evaluate the Efficacy, Safety and Immunogenicity of MTBVAC administered in healthy HIV unexposed uninfected and HIV exposed uninfected newborns in Tuberculosis-Endemic Regions of Su… European & Developing Countries Clinical Trials Partnership
    2021 - 2028
  • RSV dynamics in the context of COVID - South Africa Bill & Melinda Gates Foundation
    2021 - 2022
  • COVID-19 Scientific Writing; SA Strain Bill & Melinda Gates Foundation
    2021 - 2022
  • COVID 19: Investigation of hospitalized adults in South Africa. Bill & Melinda Gates Foundation
    2020 - 2022
  • Klebsiella neonatal sepsis in Baragwanath Hospital Bill & Melinda Gates Foundation
    2020 - 2023
  • COVID-19 ChAdOx Clinical Trials in RSA Bill & Melinda Gates Foundation
    2020 - 2023
  • An adaptive phaseI/II randomized placebo-controlled trial to determine safett, immunogenicity and efficacy on non-replicating ChAdOx1 SARSCoV-2 vaccine in South African adults living without HIV: and safety and immunogenicity in adults living with HIV South African Medical Research Council
    2020 - 2022
  • Investigating Point of Care Diagnostic Strategies to Optimize the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa Bill & Melinda Gates Foundation
    2020 - 2023
  • Memory B responses induced by GBS colonization during pregnancy Bill & Melinda Gates Foundation
    2020 - 2023
  • GBS Genomic Surveillance in LMICs. Bill & Melinda Gates Foundation
    2020 - 2023
  • Prevention of invasive Group B Streptococcus disease in young infants: a pathway for the evaluation & licensure of an investigational maternal GBS vaccine European & Developing Countries Clinical Trials Partnership
    2019 - 2024
  • Effectiveness of Covid-19 vaccination in Eswatini against SARS-CoV-2 associated hospitalization and death AstraZeneca (United States)
    2019 - 2022
  • Exploring the potential use of Next Generation Sequencing for Molecular Chracterisation of Infectious Causes of Stillbirths and Neonatal Death Bill & Melinda Gates Foundation
    2019 - 2023
  • Impact of duration of antibiotic therapy and of oral step-down to amoxicillin or co-amoxiclav on effectiveness, safety and selection of antimicrobial resistance in severe and very severe childhood community-acquired pneumonia (CAP): a randomised controll… European & Developing Countries Clinical Trials Partnership
    2019 - 2024
  • Temporal changes of Streptococcus pneumoniae and other bacterial pharyngeal colonization in children and adults in urban and rural South African settings with high HIV-prevalence in the ara of childhood pneumocccal conjugate vaccine immunization. Bill & Melinda Gates Foundation
    2018 - 2023
  • A multicenter Phase III double-blind, randomized, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG. priMe European & Developing Countries Clinical Trials Partnership
    2017 - 2024
  • Tregs, Gut Microbiome and Immune Responses in HIV-Exposed and Unexposed Infants National Institutes of Health
    2017 - 2022
  • Child Health and Mortality Prevention Surveillance Emory University
    2016 - 2024
  • Determining the contribution of zinc deficiency to perinatal Group B Streptococcus infections National Institutes of Health
    2016 - 2023
  • Group B Steptococcus: Standardization of Laboratory assays Bill & Melinda Gates Foundation
    2016 - 2024
  • The Broader Impact of Maternal Immunization in Sub-Saharan Africa and Asia: a multisite study in randomized clinical control trial cohorts Yale University

Publications (670)